Literature DB >> 24850305

Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.

Minjie Gao1, Lu Gao1, Guang Yang1, Yi Tao1, Jun Hou1, Hongwei Xu2, Xiaojing Hu1, Ying Han1, Qianqiao Zhang1, Fenghuang Zhan2, Xiaosong Wu3, Jumei Shi3.   

Abstract

The anti-multiple myeloma (MM) potential of natural killer (NK) cells has been of rising interest in recent years. However, the molecular mechanism of NK cell cytotoxicity to myeloma cells remains unclear. In the present study, we investigated the expressions of human leukocyte antigen (HLA) class I and HLA-G in patient myeloma cells, and determined their relevance in patient tumor-cell susceptibility to NK cell cytotoxicity. Our results showed that patient myeloma cells (n = 12) were relatively resistant to NK-92 cell lysis, compared with myeloma cell lines (n = 7, P < 0.01). Gene expression profiling and flow cytometry analysis showed that both mRNA and protein of HLA class I were highly expressed in 12 patient myeloma cells. Interestingly, no or low HLA-G surface expression was detected, although multiple HLA-G transcripts were detected in these myeloma cells. NK cell function assay showed that down-regulating HLA class I expression on patient cells by acid treatment significantly increased the susceptibility of MM cells to NK-mediated lysis. Furthermore, we found that the blocking of membrane-bound HLA class I rather than HLA-G using antibodies on myeloma samples markedly increased their susceptibility to NK-mediated killing. These results demonstrated that the resistance of patient MM cells to NK lysis mainly involves an HLA class I-dependent mechanism, suggesting that HLA class I may be involved in protecting MM cells from NK-mediated attack and contribute to their immune escape in vivo.
© The Author 2014. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Entities:  

Keywords:  HLA class I; cytotoxicity; myeloma; natural killer cells

Mesh:

Substances:

Year:  2014        PMID: 24850305     DOI: 10.1093/abbs/gmu041

Source DB:  PubMed          Journal:  Acta Biochim Biophys Sin (Shanghai)        ISSN: 1672-9145            Impact factor:   3.848


  10 in total

1.  Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.

Authors:  Nina Shah; Li Li; Jessica McCarty; Indreshpal Kaur; Eric Yvon; Hila Shaim; Muharrem Muftuoglu; Enli Liu; Robert Z Orlowski; Laurence Cooper; Dean Lee; Simrit Parmar; Kai Cao; Catherine Sobieiski; Rima Saliba; Chitra Hosing; Sairah Ahmed; Yago Nieto; Qaiser Bashir; Krina Patel; Catherine Bollard; Muzaffar Qazilbash; Richard Champlin; Katy Rezvani; Elizabeth J Shpall
Journal:  Br J Haematol       Date:  2017-03-14       Impact factor: 6.998

2.  Modulation of TLR/NF-κB/NLRP Signaling by Bioactive Phytocompounds: A Promising Strategy to Augment Cancer Chemotherapy and Immunotherapy.

Authors:  Sajad Fakhri; Seyed Zachariah Moradi; Akram Yarmohammadi; Fatemeh Narimani; Carly E Wallace; Anupam Bishayee
Journal:  Front Oncol       Date:  2022-03-01       Impact factor: 6.244

3.  NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment.

Authors:  Niken M Mahaweni; Femke A I Ehlers; Subhashis Sarkar; Johanna W H Janssen; Marcel G J Tilanus; Gerard M J Bos; Lotte Wieten
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 4.  Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A.

Authors:  Niken M Mahaweni; Femke A I Ehlers; Gerard M J Bos; Lotte Wieten
Journal:  Front Immunol       Date:  2018-12-04       Impact factor: 7.561

Review 5.  Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.

Authors:  Helmi Alfarra; Jackson Weir; Stacy Grieve; Tony Reiman
Journal:  Front Immunol       Date:  2020-11-12       Impact factor: 7.561

Review 6.  Natural Killer Cells in the Malignant Niche of Multiple Myeloma.

Authors:  Ondrej Venglar; Julio Rodriguez Bago; Benjamin Motais; Roman Hajek; Tomas Jelinek
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

7.  Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma.

Authors:  Rui Liu; Ying Shen; Jinsong Hu; Xiaman Wang; Dong Wu; Meng Zhai; Ju Bai; Aili He
Journal:  Front Oncol       Date:  2021-11-04       Impact factor: 6.244

Review 8.  Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.

Authors:  Hao-Tian Wu; Xiang-Yu Zhao
Journal:  Int J Biol Sci       Date:  2022-02-21       Impact factor: 6.580

Review 9.  Challenges of the Immunotherapy: Perspectives and Limitations of the Immune Checkpoint Inhibitor Treatment.

Authors:  Paula Dobosz; Maria Stępień; Anna Golke; Tomasz Dzieciątkowski
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

Review 10.  NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies.

Authors:  Kanako Shimizu; Tomonori Iyoda; Satoru Yamasaki; Norimitsu Kadowaki; Arinobu Tojo; And Shin-Ichiro Fujii
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.